Slide 1: Q2 and H1 2023 results
Q2 and H1 2023 Second quarter and first half year 2023 results 11 August 2023 Kathrine Gamborg Andreassen, CEO Lars Hjarrand, CFO
Slide 2: Significant growth across the business
Q2 and H1 2023 results Significant growth across the business Growth across all business areas in H1 Navamedic successfully REVENUE GROSS MARGIN Adjusted EBITDA1 Q2 124.0 MNOK acquired Sensidose AB in May, providing significant 40.4% 10.5 MNOK growth potential in the 2023 Nordics and Europe Up 12.3%
Slide 3: On track towards 20% organic Y/Y revenue growth target
On track towards 20% organic Y/Y revenue growth target Consistent positive trend in revenue and EBITDA* Strong revenue growth +39% driven by successful build- 450 45% up of product categories, 40% positive market trends and consumer demand 350 35% Normal fluctuation in 30% revenue growth between qua
Slide 4: Navamedic in brief
Navamedic in brief Nordic pharma company targeting further growth in Northern Europe A reliable supplier of high- Presence and sales in all Strong local competence Ambitious growth quality pharma products, Nordic countries, Benelux, in regulatory, strategy, high-potential within Prescription drugs,
Slide 5: On track to becoming a NOK billion revenue company
On track to becoming a NOK 1 billion revenue company STRATEGY STRENGTHEN THE CORE 1 Untapping the potential within existing products, categories and territories. SECURE AND INCREASE THE VALUE THROUGH 2 OWNERSHIP Innovative pipeline for in-licensing of new RX or OTC, including products with RX to OTC
Slide 6: High-quality portfolio with several hero products
High-quality portfolio with several hero products Prescription Drugs (RX) Consumer Health Hospital Sold through pharmacies Sold through pharmacies Tenders incl. medical nutrition* YTD 23 YTD 23 50.8 103% revenue in 134.9 37% revenue in 11% MNOK 59.2 MNOK YTD 23 revenue in MNOK YoY growth YoY growth
Slide 7: Prescription Drugs (RX): Continued growth for Mysimba
Prescription Drugs (RX) Continued growth for Mysimba The RX segment comprises Navamedic’s prescription products 36% YOY GROWTH IN MYSIMBA WHOLESALER VALUE • Continued and strong MNOK 200 Q2 2023 REVENUE demand for Mysimba®, 180 34% increase YTD in 160 66.0 MNOK revenue 140 120 100 (Q2 2022: 68.3 MNO
Slide 8: Consumer Health: Strong sales across brands
Consumer Health Strong sales across Consumer Health brands The Consumer Health segment comprises Navamedic’s over-the-counter products, available to patients without a prescription • Modifast contributed significantly to the category Q2 2023 REVENUE • SmectaGo delivered significant sales growth 31.3
Slide 9: Hospital: Strong growth of medical nutrition products
Hospital Strong growth of medical nutrition products The Hospital segment comprises Navamedic’s antibiotics portfolio and medical nutrition products for the treatment of Inborn Errors of Metabolism (IEM) • The medical nutrition products delivered Q2 2023 REVENUE double digit growth 25.8 MNOK • The a
Slide 10: Successful acquisition of Sensidose AB
Successful acquisition of Sensidose AB
Slide 11: Parkinson's disease – a major public health and socio-economic challenge
Sensidose AB Parkinson’s disease – a major public health and socio-economic challenge • PD is a complex progressive neurodegenerative disease The five stages of Parkinson’s disease characterised by tremors, rigidity, and slowness of movement • PD affects 1-2 per 1000 of the population at any time an
Slide 12: Commercial strategy and activities underway
Successful acquisition of Sensidose AB Commercial strategy and activities underway • Sensidose’s treatment against Parkinson’s disease, Flexilev, is available in Norway, Sensidose AB Sweden and Denmark • A Sweden-based • Flexilev has market access in a total of 10 pharmaceutical company countries an
Slide 13: Financials
FINANCIALS @ Navamedic
Slide 14: Key consolidated profit and loss figures
Financials Note: Sensidose numbers included Key consolidated profit and loss figures for 2 months (May andJune) (in NOK '1000) Q2 2023 Q2 2022 YTD 2023 YTD 2022 FY 2022 In Q2 2023, revenues grew by 12.3% Operating revenues 123 967 110 361 245 686 173 357 382 135 compared to the same quarter last yea
Slide 15: Financials: Assets
Financials Assets Note: The balance sheet includes consolidated Sensidose AB numbers (in NOK '1000) 30.06.2023 30.06.2022 31.12.2022 The increase in Goodwill is mainly due to Goodwill 142 839 98 175 100 743 the Sensidose acquisition Deferred tax assets 835 9 168 835 Other intangible assets 83 732 31
Slide 16: Equity and liabilities
Financials Equity and liabilities (in NOK '1000) 30.06.2023 30.06.2022 31.12.2022 Total equity 211 444 185 692 209 720 Non-current license liabilities 3 781 6 039 3 762 Loans and borrowings 103 647 53 042 38 368 Non-current right of use liabilities 4 676 5 179 4 861 Equity ratio of 46.4% Total non-c
Slide 17: Cash flow Group – total operations
Financials Cash flow Group – total operations (in NOK '1000) Q2 2023 Q2 2022 Year 2022 The cash flow from Operating Activities is mainly the result of Net profit Net cash flow from operating activities -988 5 359 17 941 coupled with changes in net working Net cash flow from investing activities -89
Slide 18: Summary & Outlook
SUMMARY & OUTLOOK @ Navamedic
Slide 19: Navamedic ASA summary and outlook
Navamedic ASA summary and outlook Continued strong growth supported by a TARGETS AND AMBITIONS scalable platform On track to reach growth target 20% annual organic growth • Navamedic delivered NOK 245.7 million in revenue in the first half of 2023, representing an increase of 41.7% YoY Mid-term ambi
Slide 20: Q&A
Q&A 20 @ Navamedic
Slide 21: Thank you for your attention!
Thank you for your attention! Navamedic’s Q3 2023 presentation will be held on November 1st, 2023 21
Slide 22: Appendix
APPENDIX @ Navamedic
Slide 23: Condensed consolidated statement of cash flows
Navamedic ASA Condensed consolidated statement of cash flows (in NOK '1000) Q2 2023 Q2 2022 YTD 2023 YTD 2022 Year 2022 Cash flow from operating activities Profit before tax -17 113 9 575 491 10 096 42 506 Adjusted for: Depreciation, amortization and impairment 2 204 1 830 4 037 3 660 7 242 Financia
Slide 24: Basis for preparation and Alternative Performance Measures
Appendix Basis for preparation This presentation provides financial highlights for the quarter for Navamedic Group. The financial information is not reported according to the requirements in IAS 34 (Interim Financial Reporting) and the figures are not audited. The same measurement principles as pres
Slide 25: Copyright and disclaimer
Appendix Copyright and disclaimer Copyright Copyright of all published material including photographs, drawings and images in this document remains vested in Navamedic and third party contributors as appropriate. Accordingly, neither the whole nor any part of this document shall be reproduced in any